<DOC>
	<DOCNO>NCT03104010</DOCNO>
	<brief_summary>This study aim explore optimal dose PEG-rhGH injection treatment AGHD , preliminarily evaluate safety efficacy , provide scientific reliable evidence medication dosage Phase 2 clinical study .</brief_summary>
	<brief_title>A Non-inferiority Phase 2 Study Evaluate Safety Efficacy PEG-rhGH Treatment AGHD</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Before treatment , subject diagnose AGHD base medical history , clinical symptom , vital sign , insulin tolerance test imagological examination . The subject diagnose GHD childhood remain GHD adulthood , linear growth complete : bone age ( BA ) ≥18 year old ; AGHD patient experience paroxysm 18 year old : patient experience pituitary surgery ( 2 year pituitary adenoma surgery , 5 year craniopharyngioma surgery 12 month pituitary surgery ) , traumatic brain injury ( TBI ) , Sheehan syndrome , etc.. The plasma GH concentration peak &lt; 5ng/ml insulin tolerance test ( ITT ) ( 's unnecessary conduct ITT follow condition : anterior pituitary dysfunction , pituitary hormone deficiency ( 3 hormone ) serum IGF1 level lower limit normal value : i.e . 2 SD ) . Age : 1860 year old . Patients history GH treatment one year . Body mass index ( BMI ) : 18.5 kg/m2≤BMI≤30kg/m2 . When hormone deficiency ( glucocorticoid , thyroid hormone sex steroid ) , subject receive hormone replacement therapy therapeutic dose shall stable within 3 month enrolment . The subject agree cooperate complete concert trial procedure followup , treatment plan laboratory examination , sign write informed consent . Patients serious heart disease , include NYHA III , serious arrhythmia , unstable angina pectoris myocardial infarction within late 6 month . Patients history ischemic cerebrovascular disease , febrile convulsion epilepsy seizure . Patients carpal tunnel syndrome . Patients poor hypertension control ( systolic pressure &gt; 140mmHg diastolic pressure &gt; 90mmHg treatment ) . Patients previous present history malignant tumor : two direct relative within three generation previous present history tumor . Patients undergo antidepressive therapy , immunosuppressive therapy , chemotherapy radiotherapy ( history radiotherapy ) . Patients ever take antiobesity drug within late 3 month . Patients serious infection . Patients consciousness disorder mental disease . Subjects impair glucose regulation ( IGR ) ( impaired fasting glucose ( IFG ) and/or impair glucose tolerance ( IGT ) ) diabetes ; patient family history diabetes ( direct relative ) . Subjects abnormal liver kidney function ( ALT &gt; 2 time upper limit normal value ; eGFR calculate MDRD formula &lt; 60 ) . Subjects positive antiHBc , HBsAg HBeAg Hepatitis B virus test . Subjects highly allergic constitution allergy proteins investigational productorits excipient study . Subjects take part clinical trial within 3 month . Patients mental physical deficiency influence evaluation investigational product . Pregnant lactating woman ; female plan get pregnant within one year . Subjects whose tumor marker exceed upper limit normal range reexamination result still high . Other condition unsuitable study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>